ChromaDex Corporation — Q2 2022 Form 10-Q
Filing identity: The filing is for ChromaDex Corporation (Nasdaq: CDXC), although the request metadata names Niagen Bioscience, Inc. The unaudited quarter ended June 30, 2022; the report was signed August 10, 2022.
Business context and reporting period
ChromaDex is a bioscience company focused on healthy aging. Its main product lines include Tru Niagen consumer supplements, Niagen ingredients sold to manufacturers, and analytical reference standards and services. The filing compares Q2 and first-half 2022 results with the same 2021 periods.
Financial performance and liquidity
| Metric | Q2 2022 | Q2 2021 | Six months 2022 | Six months 2021 |
|---|---|---|---|---|
| Net sales | $16.7m | $17.7m | $34.0m | $32.4m |
| Gross profit | $10.0m | $10.8m | $20.6m | $20.0m |
| Gross margin | 60.0% | 61.1% | 60.5% | 61.9% |
| Operating expenses | $16.4m | $16.4m | $34.7m | $33.0m |
| Operating loss | $(6.4)m | $(5.6)m | $(14.1)m | $(12.9)m |
| Net loss | $(6.4)m | $(5.6)m | $(14.1)m | $(12.9)m |
| Loss per share, basic and diluted | $(0.09) | $(0.08) | $(0.21) | $(0.20) |
- Revenue mix and trends: Consumer Products sales were $14.5m in Q2, down 6%; Ingredients sales were $1.5m, down 3%; and Analytical Reference Standards and Services sales were $0.7m, down 6%. First-half total sales rose 5%, led by 6% growth in Consumer Products.
- Cash flow: First-half cash used in operating activities was $11.0m versus $13.3m in 2021. Investing used $0.1m; financing used $0.01m. Cash and cash equivalents, including restricted cash, declined to $17.1m from $28.2m at year-end 2021.
- Balance sheet and debt: Unrestricted cash was $16.9m. The company had no borrowings under its Western Alliance Bank credit line; the filing says $3.8m was then available to borrow under the facility, whose maximum is $10.0m subject to conditions. Operating lease liabilities totaled $4.5m. Total assets were $46.6m and stockholders’ equity $20.8m at June 30.
- Other obligations: Inventory purchase commitments were $15.1m, payable over approximately one year; future minimum lease payments were $5.3m over approximately six years. Inventory was $15.8m, up from $13.6m at year-end.
Material changes versus the prior comparable period
- Q2 sales fell 5%, principally as lower sales to related-party A.S. Watson and the prior-year Walmart launch stocking effect outweighed higher e-commerce sales. First-half sales increased 5%, mainly from e-commerce growth, partly offset by lower Walmart sales after initial stocking.
- Q2 gross profit declined 7%; first-half gross profit increased 3%. Gross margin narrowed in both comparisons, with the filing citing product mix, raw-material and supply-chain overhead costs, and lower utilization in the analytical services segment.
- Sales and marketing expense rose 29% in Q2 and 30% in the first half, reflecting expanded consumer-product advertising, marketing campaigns, and staffing. R&D expense rose 24% and 30%, respectively.
- General and administrative expense fell 22% in Q2 and 14% in the first half, primarily because of lower litigation costs, partly offset by technology investment and added staff. Despite lower G&A, total operating expenses were nearly flat in Q2 and higher year to date.
- Net loss widened by $0.8m in Q2 and $1.2m for the first half. First-half operating cash use improved by $2.3m, principally due to timing of receivable collections, partly offset by increased inventory.
Outlook, risks, contingencies, and unusual items
- Liquidity outlook: Management disclosed recurring losses, negative operating cash flow, COVID-19 effects, and inflationary pressures as conditions raising substantial doubt about the company’s ability to meet obligations. Management nevertheless expects unrestricted cash and cash generated from sales to cover obligations for at least the next 12 months, and said it is pursuing expense reductions and lower cash burn in the second half of 2022. Additional capital may be needed; access to the ATM facility is conditional and market-dependent, with approximately $47.8m remaining available at June 30.
- Expense outlook: Management anticipated lower consumer-product marketing expense in the second half of 2022 as it shifted toward more efficient channels and campaigns. No numerical revenue or earnings guidance was provided.
- China joint venture: A 20-year joint venture agreement was signed in May, with ChromaDex expected to hold 71%. Closing was expected by the end of Q3 2022, but the JV had not launched as of the report. Commercialization depends on regulatory approvals, including China’s “Blue Hat” registration; failure to obtain it within the specified period could affect the arrangement.
- Litigation and IP: The Elysium disputes involved jury awards in 2021 against both sides, followed by a settlement that courts enforced in 2022; notices of appeal and cross-appeal were filed. ChromaDex stated that it could not predict the appeal outcome or estimate possible loss for the relevant proceeding. Separately, a court invalidated the patents asserted against Elysium, and ChromaDex appealed. In a Thorne patent review, the PTAB found a challenged claim of the ’086 patent unpatentable; a decision on the ’807 patent review was still pending.
- Other contingencies: The company recorded an approximately $0.5m return liability relating to a customer dispute over Niagen purchases. It also disputed a licensor’s claim for $1.6m plus interest in sublicense fees. The filing describes an unserved product-liability complaint and an ongoing customer dispute, which the company said it would defend.
- Regulatory matter: The company disclosed prior FDA/FTC and FTC warning letters concerning COVID-19-related statements about NR research. It said it removed or requested removal of certain posts and did not expect the matter’s resolution to be material.
- Subsequent event: On August 5, 2022, the company filed a claim for an approximately $2.5m Employee Retention Tax Credit refund. The filing does not report receipt of the funds.
Important facts for investors to verify
- Whether sales growth, e-commerce performance, and the planned second-half reduction in marketing expense translate into improved margins and lower cash burn.
- Quarterly unrestricted cash, operating cash use, inventory levels and commitments, and the terms and practical availability of credit or equity financing.
- Developments in the Elysium settlement appeals and patent proceedings, including any potential financial exposure or effect on intellectual-property protection.
- Completion and launch of the China joint venture, required regulatory registrations, and the related-party terms and funding obligations.
- Status and accounting treatment of the ERTC claim, customer return liability, and other disclosed legal or regulatory contingencies.